AVITA Medical Q1 revenue $19.3M (+4% YoY); net loss narrows to $10.6M

AVITA Medical, Inc.

Total revenue $19.3M, up 4% YoY and 10% sequentially, driven by Cohealyx and improved RECELL utilization.
Net loss $10.6M ($0.35 loss per share) vs $13.9M ($0.53 loss) in Q1 2025; operating expenses down 11% to $24.5M.
Gross profit margin 81.7% (vs 84.7%) due to product mix; RECELL-only margin 85.0%.
Reaffirmed FY2026 revenue guidance $80-85M, representing growth of 12-19%.
Appointed Cary Vance as President and CEO; Jan Stern Reed as independent Chair of the Board.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.